NASA’s SpaceX CRS-30 mission is set to launch with a focus on cartilage repair, retinal gene therapies, treatments for neurological diseases, and technology testing on external platforms. This mission, launching from Cape Canaveral, Florida, on March 20, 2024, will transport over 40 payloads to the International Space Station (ISS). These payloads include projects for in-space production, technology demonstrations, life science experiments, and student-led research. The goal is to enhance life on Earth and promote a sustainable economy in low Earth orbit (LEO) through space-based research.
Among the notable payloads are two investigations by Redwire Corporation in collaboration with Eli Lilly & Company and Butler University. They aim to crystallize organic molecules in microgravity, potentially leading to better therapeutics for various conditions. This continues Eli Lilly’s commitment to leveraging space for patient care improvements on Earth.
Boeing and CSIRO are working together to test a Multi-Resolution Scanner using the Astrobee robotic system. This technology could create 3D maps of the space station, aiding future exploration and maintenance tasks in remote environments.
The National Stem Cell Foundation is exploring neuroinflammation mechanisms related to neurodegenerative diseases. By using 3D brain models derived from stem cells, this research could provide insights into Alzheimer’s, Parkinson’s, and multiple sclerosis.
Airbus U.S. Space & Defense is enhancing the Bartolomeo platform on the ISS. The ArgUS platform will support various payloads, including SpaceTV-1, which aims to livestream high-definition views of Earth and the space station.
The University of Connecticut is investigating the production of Janus base nanomaterials in microgravity. These materials could potentially repair cartilage and reduce joint inflammation, offering new solutions for orthopedic injuries and diseases like arthritis.
Additionally, two investigations were selected through the Technology in Space Prize, part of the MassChallenge startup accelerator program. Oculogenex is testing a novel gene therapy for age-related macular degeneration (AMD), which could benefit millions. Encapsulate is validating an automated tumor-on-a-chip system to grow cancer cells for chemotherapy testing, aiming for personalized cancer treatments.
The Falcon 9 rocket will launch these investigations on March 21, 2024, from Cape Canaveral Space Force Station. A recent webinar provided more details on select payloads, with a recording available on the ISS National Lab’s launch page.
The ISS National Lab enables unique research and technology development to improve life on Earth and foster space-based business models. Managed by the Center for the Advancement of Science in Space (CASIS), it offers access to the ISS for non-NASA science, technology, and education initiatives. CASIS, a nonprofit organization, accepts donations to support science in space for humanity’s benefit.
For more information about the ISS National Lab and how to support its missions, visit the official website and donations page.